Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Eichelbaum

Showing results (131-140 of 263) with videos related to

Pageof 27
Sort By:
Journal of Pharmaceutical Sciences|March 1, 1993
Simultaneous assessment of the intravenous and oral disposition of the enantiomers of racemic nimodipine by chiral stationary-phase high-performance liquid chromatography and gas chromatography/mass spectroscopy combined with a stable isotope techniqueC Fischer, F Schönberger, W Mück, et al.
Clinical Pharmacology and Therapeutics|June 1, 1996
Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formationG Engel, U Hofmann, H Heidemann, et al.
Journal of Neurology|January 1, 1981
A prospective randomised trial on the effect of monitoring plasma anticonvulsant levels in epilepsyW Fröscher, M Eichelbaum, R Gugler, et al.
Fortschritte Der Neurologie-Psychiatrie|December 1, 1982
[Prospective studies on epilepsy therapy with carbamazepine]W Fröscher, M Eichelbaum, G Hildenbrand, et al.
European Journal of Clinical Pharmacology|February 1, 1980
Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquineL Bertilsson, H J Dengler, M Eichelbaum, et al.
The Journal of Clinical Investigation|March 1, 1990
Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liverD M Grant, K Mörike, M Eichelbaum, et al.
Pharmacogenetics|May 8, 2001
Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brainI Siegle, P Fritz, K Eckhardt, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|December 1, 1995
Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humansD Busse, J Cosme, P Beaune, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1979
The metabolism of DL-[14C]verapamil in manM Eichelbaum, M Ende, G Remberg, et al.
British Journal of Clinical Pharmacology|April 1, 1988
Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquineM Eichelbaum, L Bertilsson, A Küpfer, et al.
Pageof 27

Showing results (131-140 of 263) with videos related to

Sort By:
Pageof 27
Journal of Pharmaceutical Sciences|March 1, 1993
Simultaneous assessment of the intravenous and oral disposition of the enantiomers of racemic nimodipine by chiral stationary-phase high-performance liquid chromatography and gas chromatography/mass spectroscopy combined with a stable isotope techniqueC Fischer, F Schönberger, W Mück, et al.
Clinical Pharmacology and Therapeutics|June 1, 1996
Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formationG Engel, U Hofmann, H Heidemann, et al.
Journal of Neurology|January 1, 1981
A prospective randomised trial on the effect of monitoring plasma anticonvulsant levels in epilepsyW Fröscher, M Eichelbaum, R Gugler, et al.
Fortschritte Der Neurologie-Psychiatrie|December 1, 1982
[Prospective studies on epilepsy therapy with carbamazepine]W Fröscher, M Eichelbaum, G Hildenbrand, et al.
European Journal of Clinical Pharmacology|February 1, 1980
Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquineL Bertilsson, H J Dengler, M Eichelbaum, et al.
The Journal of Clinical Investigation|March 1, 1990
Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liverD M Grant, K Mörike, M Eichelbaum, et al.
Pharmacogenetics|May 8, 2001
Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brainI Siegle, P Fritz, K Eckhardt, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|December 1, 1995
Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humansD Busse, J Cosme, P Beaune, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1979
The metabolism of DL-[14C]verapamil in manM Eichelbaum, M Ende, G Remberg, et al.
British Journal of Clinical Pharmacology|April 1, 1988
Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquineM Eichelbaum, L Bertilsson, A Küpfer, et al.
Pageof 27